Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,530
datasets available to search
ShareScore release 0.9.0
Dataset results
3,530 results for “Non-small cell lung cancer”
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
ClinicalTrials.gov study NCT01306045. IPD Sharing: YES. Countries: 1. Publications: 5.
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03137771. IPD Sharing: NO. Countries: 4. Publications: 1.
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
ClinicalTrials.gov study NCT03706690. IPD Sharing: YES. Countries: 10. Publications: 1.
0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00771953. IPD Sharing: Not stated. Countries: 1. Publications: 7.
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03915951. IPD Sharing: YES. Countries: 5. Publications: 4.
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
ClinicalTrials.gov study NCT00157209. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT01041781. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT01355484. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
ClinicalTrials.gov study NCT00694603. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00729612. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00654030. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT00400803. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00391274. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
ClinicalTrials.gov study NCT00409188. IPD Sharing: Not stated. Countries: 33. Publications: 4.
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04362072. IPD Sharing: YES. Countries: 7. Publications: 0.
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00216125. IPD Sharing: NO. Countries: 1. Publications: 1.
HINC dataset from: Homeopathic treatment as an add-on therapy may improve quality of life and prolong survival in patients with non-small cell lung cancer: A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study
Open the record for dataset details and reuse information.
Single-cell multi-modal analysis of tumor microenvironment in human non-small cell lung cancer tissues
Open the record for dataset details and reuse information.
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Objective: The aim of this study was to prospectively evaluate the feasibility of monitoring treatment response to chemotherapy in patients with non-small cell lung carcinoma using functional diffusion maps (fDMs). Materials and Methods: This study was approved by the Cantonal Research Ethics Committee and informed written consent was obtained from all patients. Nine patients (mean age = 66 years; range = 53–76 years, 5 females, 4 males) with overall 13 lesions were included. Imaging was performed within two weeks before initiation of chemotherapy and at one, two, and six weeks after initiation of chemotherapy. Imaging included a respiratory-triggered diffusion-weighted sequence including three b-factors (100, 600, and 800 s/mm2). Treatment response was defined by change in tumor diameter on computed tomography (CT) after two cycles of chemotherapy. Changes in the apparent diffusion coefficient (ADC) on a per-lesion basis and the percentages of voxel with significantly increased or decreased ADCs on fDMs were analyzed using repeated measures analysis of variance (ANOVA). Changes in tumor size were used as covariate to examine the ability of ADCs and fDM parameters to predict treatment response. Results: Repeated measures ANOVA revealed that the percentage of voxels with increased ADCs on fDMs (p = 0.002) as well as the mean ADC increase (p = 0.011) were significantly higher in good responders with a large reduction in tumor size on CT. Conclusion: Our results indicate that the percentage of voxels with significantly increased ADCs on fDMs seems to be a promising biomarker for early prediction of treatment response in patients with non-small cell lung carcinoma. Contrary to averaged values, this approach allows the spatial heterogeneity of treatment response to be resolved.
Proteomic and Metabolomic Profiling of Plasma Predict Immune-related Adverse Events in Older Patients with Advanced Non-small Cell Lung Cancer
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.